You are running an unsupported browser, please upgrade your browser. Close

Email Subscription

Never miss the latest news and offers - subscribe now!

Never miss the latest news and offers - subscribe now!

Privacy Policy and Cookies

By browsing this site you accept cookies used to improve and personalize our services and marketing. Learn more about our Data Privacy Policy, including cookies, by clicking the Policy button.

By browsing this site you accept cookies used to improve and personalize our services and marketing. Learn more about our Data Privacy Policy, including cookies, by clicking the Policy button.

New Product Introduction: Cadence™ Inline Diafiltration Module

The latest addition to Pall’s portfolio of single-pass tangential flow filtration products, the Cadence™ inline diafiltration module.

November 14, 2017

The latest addition to Pall’s portfolio of single-pass tangential flow filtration (SPTFF) products, the CadenceInline Diafiltration (ILDF) device delivers fully continuous diafiltration (DF) in the downstream processing (DSP) steps. Even though SPTFF has revolutionized how TFF is implemented in biotech, vaccine, blood plasma and other applications, challenges remain. This new device addresses these challenges, and completes Pall’s product and technology offering for continuous processing of the final ultrafiltration (UF)/DF of drug substance. The device also brings the biopharm industry one step closer to the realization of a commercially feasible end-to-end integrated continuous bioprocessing platform.

 

Constructed with Pall’s proprietary conventional TFF cassette building blocks in either Delta regenerated cellulose or Omega™ polyethersulfone membrane, and complemented by technology licensed from SPF Innovations, the new Cadence ILDF module ensures accurate scalability, with proven selectivity and low protein binding attributes. The modules can be purchased in a range of size formats to accommodate various processing volumes, and can also be used in one or more locations of a continuous monoclonal antibody (mAb) downstream purification process.

 

The Cadence ILDF technology enables removal factors of ≥ 3-log. Users will experience significantly reduced system hold-up volume and a lower risk of product damage or aggregation due to the shorter residence time and shear exposure. Cadence ILDF modules come pre-assembled with an easy to use, holder-less design. Each device also includes a preconfigured tubing set that connects to a feed pump and a diafiltration buffer pump for simple operation. 

Pall’s new Cadence Inline Diafiltration (ILDF) device delivers scalable continuous final ultrafiltration (UF)/DF of drug substance with proven selectivity and low binding attributes.

 

Built with conventional cassettes in Delta regenerated cellulose or Omega™ polyethersulfone membrane, the preconfigured, holder-less modules enable removal factors of ≥ 3-log, with a single pass through the device.